ECM components
Collagen, elastin and GAGs are the named material components.
ACELLULAR DERMAL MATRIX
CellREDM™
An ECM-based dermal-matrix material
The brochure identifies CellREDM as human allogenic tissue: an acellular dermal matrix in injectable/powder form, containing collagen, elastin and glycosaminoglycans.
PRODUCT INFORMATION
An acellular dermal matrix profile.
The supplied brochure classifies CellREDM as “Human allogenic tissue, Acellular Dermal Matrix (Injectable/Powder)”. It lists collagen, GAGs and elastin as components derived from the dermal matrix.
This material identity is shown explicitly: the website does not relabel it as a conventional cosmetic serum or assume that all products in the portfolio share the same regulatory classification.
160 mgAmount listed in specification
<75 μmListed particle size
ADMAcellular dermal matrix
SOURCE · CellREDM brochure, pages 2 and 11.
PRODUCT INFORMATION
The technical specification.
| Field | As listed in the supplied brochure |
|---|---|
| Product | CellREDM™ |
| Brochure classification | Human allogenic tissue, Acellular Dermal Matrix (Injectable/Powder) |
| Components | Collagen, GAGs and elastin derived from dermal matrix |
| Particle size | <75 μm |
| Amount | 160 mg |
| Package contents | Allogenic dermal collagen; 1 mixing syringe; 2 adapters; 3 needles |
| Sterilisation | E-Beam sterilisation |
| Storage | Room temperature, 1–30°C |
| Shelf life | 36 months from date of manufacture |
| Precaution | Single use only; do not reuse or re-sterilise |
SOURCE · CellREDM brochure, page 11 and original packaging image.
PRODUCT INFORMATION
ECM composition and processing context.
The brochure organises the product around extracellular matrix (ECM) components, micro-particle form and decellularisation. Collagen, elastin and glycosaminoglycans are presented together rather than as a single isolated ingredient.
Micro-particle form
The brochure specifies particles smaller than 75 μm.
Decellularisation
Source sections describe H&E / DAPI observations and residual-dsDNA testing.
SOURCE · CellREDM brochure, pages 2, 4–6. Biological outcome claims are not inferred solely from composition.
PRODUCT INFORMATION
Reported evaluations, with their context.
The brochure reports changes at 1, 2 and 4 weeks. The following four-week values are manufacturer-reported brochure figures, not independently verified results or promised individual outcomes.
| Reported endpoint | Change at 4 weeks | Source |
|---|---|---|
| Skin texture | +14.71% | Brochure p.8 |
| Skin tone | +5.34% | Brochure p.8 |
| Dermal density | +11.79% | Brochure p.8 |
| Skin elasticity | +19.31% | Brochure p.9 |
| Deep hydration | +10.90% | Brochure p.9 |
Bench testing is a separate evidence category.
Page 6 reports residual dsDNA values of 1399.5 and 0.09 ng/mg before and after processing, and 85.70% cell viability in an in-vitro cytotoxicity assessment. These are laboratory observations and are not treated as proof of zero clinical risk.
The manufacturer-registration material shown in the brochure is not converted into an “FDA-approved product” badge on this website.
SOURCE · CellREDM brochure, pages 3 and 6–9. Patient images and procedural mixing instructions are not republished in this public-facing draft.
PROFESSIONAL RESOURCES
Source material and professional review.
Source documentCellREDM™ brochure · English · 11 pages
Request document ↗Current IFU & specificationRequest the current model-specific instructions and technical data.
Request document ↗Market-specific documentationRequest classification and supply-status documentation for your country.
Request document ↗Professional enquiries only. These summaries do not replace a current IFU, clinical judgement or market-specific documentation. Requests open an email draft; nothing is submitted automatically.
ICT MEDICAL / PROFESSIONAL ENQUIRIES
Speak with ICT Medical Discuss the product. Request the right documents.
Product information · Technical documentation · Partnership discussions